Biotech Breakthroughs — 2026-05-18

Top Breakthroughs This Week

1. FDA Grants Accelerated Approval to Sonrotoclax (Beqalzi) for Mantle Cell Lymphoma

• Company / Institution: BeOne Medicines USA, Inc.
• What happened: On May 13, 2026, the FDA granted accelerated approval to sonrotoclax (brand name: Beqalzi), a BCL-2 inhibitor, for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of therapy.
• Indication / Target: Relapsed or refractory mantle cell lymphoma (MCL); BCL-2 protein inhibition
• Why it matters: Sonrotoclax represents a next-generation BCL-2 inhibitor entering the MCL space, a rare and aggressive B-cell lymphoma with limited options after multiple lines of treatment. This accelerated approval opens a new targeted treatment pathway for patients who have exhausted existing therapies, and positions BeOne Medicines as a serious competitor in the hematologic oncology arena. Confirmatory trial data will be required for full approval.

5 sources

fda.gov

Novel Drug Approvals for 2026 | FDA

fda.gov

Novel Drug Approvals for 2025 | FDA

fda.gov

FDA grants accelerated approval to sonrotoclax for relapsed or refractory mantle cell lymphoma | FDA

fda.gov

Drug Approvals and Databases | FDA

fda.gov

2026 Biological Approvals | FDA

2. NICE Backs Perioperative Imfinzi for Stomach Cancer Just 17 Days After UK Approval

• Company / Institution: AstraZeneca (Imfinzi/durvalumab)
• What happened: According to Fierce Pharma's regulatory tracker updated this week, NICE (the UK's National Institute for Health and Care Excellence) backed perioperative Imfinzi (durvalumab) for stomach cancer only 17 days after its UK regulatory approval — an unusually rapid health technology assessment turnaround.
• Indication / Target: Stomach (gastric) cancer; perioperative setting; PD-L1 checkpoint inhibitor
• Why it matters: The speed of NICE's recommendation — just over two weeks after UK approval — underscores accelerating payer-regulator coordination in oncology. For patients with resectable gastric cancer, adding perioperative immunotherapy to standard chemotherapy could meaningfully improve outcomes. It also signals that AstraZeneca's immuno-oncology franchise is gaining momentum in the perioperative space beyond lung cancer.

3. Oricell Therapeutics Closes $110M Pre-IPO Round to Advance Cell Therapy Pipeline

• Company / Institution: Oricell Therapeutics; investors include Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, E-Town Capital, Luxin Venture Capital, NGS Super, Elikon Investment, Talon Capital, and a "leading global healthcare fund"
• What happened: On April 10, Oricell Therapeutics announced closing over $110 million in a final pre-IPO funding round, following a $70 million Series C1 in January 2026. The company has now raised over $180 million in total as it prepares to pursue a public offering.
• Indication / Target: Cell therapy pipeline (exact indications not disclosed in available data); the company is positioning for a public listing
• Why it matters: Oricell's rapid fundraising cadence — two large rounds in under four months — reflects continued investor appetite for cell therapy platforms with IPO potential. The diversified syndicate of global healthcare investors signals confidence in the company's pipeline and commercial trajectory ahead of what would be a major test for the 2026 biotech IPO market.

Regulatory Roundup

• Sonrotoclax / BeOne Medicines USA — FDA granted accelerated approval on May 13, 2026, for relapsed or refractory mantle cell lymphoma (MCL) in adults after ≥2 prior lines of therapy. BeOne Medicines positions this BCL-2 inhibitor as a next-generation successor to venetoclax in hematologic cancers.

• Imfinzi (durvalumab) / AstraZeneca — NICE backed perioperative Imfinzi for stomach cancer just 17 days after UK approval, one of the fastest NICE turnarounds on record for an oncology indication this year. This follows the drug's expanded approvals across multiple cancer types in recent months.

• Novel Drug Approvals / FDA (2026 pipeline) — The FDA's novel drug approval page was updated through May 13, 2026, confirming sonrotoclax as the latest NDA/BLA to clear the agency in 2026. Multiple additional oncology PDUFA dates remain on the calendar for June.

Therapeutic Modality Watch

Gene & Cell Therapy

• Oricell Therapeutics closed over $110M in its pre-IPO round (April 10), bringing total 2026 fundraising above $180M as it prepares to go public. The Chinese cell therapy company has assembled a high-profile global investor syndicate, reflecting surging pre-IPO appetite in the cell therapy space.

• Generate Biomedicines (Flagship Pioneering spin-out) priced a $400M IPO in February 2026, one of the largest biotech IPOs of the quarter. Its AI-generative biology platform includes GB-0895 in early-stage COPD testing, with cancer pipeline candidates approaching the clinic. Results from early trials are expected later in 2026.

• Aktis Oncology raised $318M in its January 2026 IPO — 2026's first biotech public offering — backed by MPM BioImpact, Vida Ventures, and RA Capital. The radiopharmaceutical specialist had previously raised $346M in private funding to advance its Nectin-4-targeting and other radiopharmaceutical cancer programs.

Small Molecules & Biologics

• Sonrotoclax (Beqalzi), BeOne Medicines' BCL-2 inhibitor, received FDA accelerated approval May 13 for MCL, establishing a new small molecule option in heavily pre-treated hematologic malignancy. The drug is designed to overcome resistance mechanisms seen with first-generation venetoclax.

• Imfinzi (durvalumab) expanded into perioperative gastric cancer with rapid NICE endorsement this week, extending AstraZeneca's checkpoint inhibitor franchise into a new surgical setting and patient population.

• FDA oncology approvals in 2026 have tracked ahead of prior-year pace, with multiple priority review and fast-track designations across solid tumors and hematologic malignancies continuing to drive a robust approval calendar through Q2.

Platform & Discovery Tech

• Generate Biomedicines' $400M IPO (February 2026) highlighted investor enthusiasm for AI-driven protein design platforms. Generate's generative biology engine is being applied to respiratory disease (COPD), cancer, and other indications — representing one of the clearest examples of AI-native drug discovery reaching late-stage clinical validation.

• Radiopharmaceuticals emerged as a hot platform in early 2026 with Aktis's IPO, which targets cancer-specific antigens including Nectin-4. The sector has attracted outsized capital as large pharma seeks to license or acquire radiopharmaceutical pipelines.

• Biotech IPO median deal size reached $287.5M in Q1 2026 across six offerings — a figure "far surpassing" prior comparable periods — according to BioPharma Dive data, signaling that public market investors are rewarding platform plays with large upfront capital commitments.

Business & Pipeline Moves

• Oricell Therapeutics — $110M pre-IPO round (April 10, 2026): The Chinese cell therapy company closed its final pre-IPO financing, totaling over $180M raised in 2026 alone. Vivo Capital and Qiming Venture Partners led a diversified global syndicate. An IPO filing is expected in the near term, which would be a significant test of continued market appetite for cell therapy platforms.

• Generate Biomedicines — $400M IPO (February 26, 2026): The AI-generative biology company — Flagship Pioneering's most prominent spin-out since Moderna — priced at the top of its range, capping a strong February for biotech public offerings. It entered the public markets with a clinical-stage COPD program and pre-clinical oncology assets, betting that AI-designed proteins can replace traditional drug discovery timelines.

• Aktis Oncology — $318M IPO (January 8, 2026): The radiopharmaceutical specialist opened 2026's IPO market with a banner deal, pricing above its initial range. Prior private backers MPM BioImpact, Vida Ventures, and RA Capital rolled into the public offering. Aktis's Nectin-4-targeting radiopharmaceutical program represents a leading pipeline in an increasingly competitive space.

• Biotech IPO market — Q1 2026 recap: Six biotech companies priced IPOs in Q1 2026 with a median raise of $287.5M — a record for comparable periods — according to BioPharma Dive. While the pace of deals remained slow, the size of each offering jumped dramatically, suggesting public investors are concentrating capital into highest-conviction platforms rather than spreading bets widely.

Analyst Take

• Dominant theme this week: Targeted oncology continues to dominate — from sonrotoclax's BCL-2 approval in MCL to Imfinzi's perioperative gastric cancer NICE endorsement. BCL-2 inhibition is becoming a backbone strategy in B-cell malignancies, and checkpoint inhibitors are expanding into surgical/perioperative settings at an accelerating pace.

• Momentum shift: Radiopharmaceuticals and AI-native drug discovery platforms are gaining significant public market momentum in 2026, as evidenced by Aktis's IPO performance and Generate Biomedicines' outsized raise. Both modalities are attracting capital at a scale that suggests they may define the next major therapeutic wave.

• Risk signals: The accelerated approval pathway for sonrotoclax means confirmatory data remains outstanding — a common risk in the MCL space where single-arm trial results can reverse upon randomized comparison. Additionally, the high median IPO raise size ($287.5M) in Q1 2026 reflects concentration risk; fewer but larger bets means disappointing data from any single platform could have outsized market impact.

What to Watch Next Week

• FDA June 2026 PDUFA calendar: Multiple oncology drugs are expected to receive FDA decisions in June, including candidates in solid tumors and rare hematologic malignancies flagged in the cardiology and rheumatology advisor trackers. Watch the FDA's novel drug approvals page and oncology-specific calendars for specific action dates.

• Oricell Therapeutics IPO filing: Having closed its pre-IPO round, Oricell is expected to file for a public offering in the near term. Any S-1 or prospectus filing would reveal pipeline details and financial metrics for what could be one of the year's largest cell therapy IPOs.

• Sonrotoclax (Beqalzi) confirmatory trial milestones: Following accelerated approval, BeOne Medicines will need to complete confirmatory randomized trials demonstrating clinical benefit in MCL. Watch for trial enrollment updates and any interim data announcements that could de-risk or threaten full approval.

Reader Action Items

• For investors: Monitor BeOne Medicines (and peer BCL-2/hematology players) as sonrotoclax's confirmed approval trajectory develops; the confirmatory trial readout timeline will be the key value inflection for this accelerated approval. Also watch the Oricell IPO filing — it could be a leading indicator for 2026's second-half cell therapy capital cycle.

• For operators & scientists: Read the full FDA prescribing information and accelerated approval notice for sonrotoclax (Beqalzi) to understand the clinical context, patient selection criteria, and residual safety/efficacy questions that confirmatory trials must address.

• For patient advocates: The sonrotoclax accelerated approval for relapsed/refractory MCL creates a new treatment option for patients who have exhausted at least two prior lines of therapy — a population with historically poor outcomes. Advocates should monitor BeOne Medicines' patient access programs and confirmatory trial enrollment opportunities.